All In Biotech

Drug Trial Radar · NCT07742215

A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)

A Phase III Open-Label, Randomized Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab Versus Daratumumab, Pomalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

Jul 2028

Study completion Oct 2032

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the efficacy and safety of the BCD-248 in combination with daratumumab versus the combination of daratumumab, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma. The study will be conducted in a population of male and female subjects aged 18 years and older, with confirmed symptomatic multiple myeloma with measurable disease, who have received one prior line of therapy that included a proteasome inhibitor and lenalidomide and were refractory to lenalidomide, or who have received two or three prior lines of therapy that included a proteasome inhibitor and lenalidomide, with disease progression during or after the last line of therapy.

Conditions

  • Myeloma Multiple

Interventions

  • BCD-248 + daratumumabDrug

    BCD-248 subcutaneously, daratumumab intravenously

  • Daratumumab + pomalidomide + dexamethasoneDrug

    Daratumumab intravenously, pomalidomide per os, dexamethasone per os

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of MRD negativity by flow cytometry at 12 months from the start of therapyTime frame: up to 12 months
  2. Progression-free survival according to the International Myeloma Working Group (IMWG) criteriaTime frame: up to 36 months

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • SI "Republican Scientific and Practical Center for Radiation Medicine and Human Ecology"

    Homyel, Belarus · Recruiting

  • SBHI "Chelyabinsk regional clinical hospital"

    Chelyabinsk, Russia · Recruiting

  • SBHI "Regional oncological dispensary"

    Irkutsk, Russia · Recruiting

  • SAHI "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"

    Kazan', Russia · Recruiting

  • Regional Government-Owned Publicly Funded Healthcare Institution "Regional Clinical Hospital"

    Krasnoyarsk, Russia · Recruiting

  • Branch Office of Hadassah Medical Ltd.

    Moscow, Russia · Recruiting

  • BHI of the Omsk region "Clinical Oncological Dispensary"

    Omsk, Russia · Recruiting

  • St. Petersburg State Healthcare Institution "City Hospital No. 15"

    Saint Petersburg, Russia · Recruiting

  • FSBI "National Medical Research Center named after V.A. Almazov" of the Ministry of Health of the Russian Federation

    Saint Petersburg, Russia · Recruiting

  • FSBI "Russian Research Institute of Hematology and Transfusiology" of the Federal Medical and Biological Agency

    Saint Petersburg, Russia · Recruiting

  • SBHI "Leningrad Regional Clinical Hospital"

    Saint Petersburg, Russia · Recruiting

  • FSBEI of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation

    Samara, Russia · Recruiting

  • FSBEI HE "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Health of Russia

    Saratov, Russia · Recruiting

  • Private healthcare institution "Clinical hospital "RZD-Medicine" of the city of Smolensk"

    Smolensk, Russia · Recruiting

  • State Budgetary Healthcare Institution "Oncological Dispensary No.2" of the Ministry of Health of the Krasnodar Region

    Sochi, Russia · Recruiting

  • SBHI "Republican Clinical Hospital named G.G. Kuvatov"

    Ufa, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.